Literature DB >> 9058841

CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause.

H D White1, K M Crassi, A L Givan, J E Stern, J L Gonzalez, V A Memoli, W R Green, C R Wira.   

Abstract

The human female reproductive tract (RT) has been analyzed by others with respect to NK cell cytolytic activity, but not CD3+ T cell (CTL) cytolytic activity. Here, we describe the cytolytic capacity of mucosal CD3+ T cells both longitudinally within the RT (Fallopian tube, uterine endometrium, endocervix, ectocervix, and vaginal mucosa) and temporally throughout the menstrual cycle, using a redirected lysis assay system. Cytolysis by CD3+ CD8+ T cells is found throughout the RT and appears to be hormonally regulated, since in the uterine endometrium, the capacity for CD3+ T cell cytolytic activity is present during the proliferative phase of the menstrual cycle and absent during the subsequent secretory (postovulatory) phase. In contrast, in postmenopausal women the entire RT, including the uterus, retains the capacity for strong CD3+ T cell cytolytic activity. These findings suggest that the high levels of estradiol and progesterone present during days 14 to 28 of the menstrual cycle down-regulate CTL activity in the uterus. As a consequence, the absence of this activity may allow implantation of a semiallogeneic embryo that would otherwise be rejected. Further, these studies indicate that CTL activity is regulated differentially in different regions of the RT, persisting in the cervix and vagina throughout the menstrual cycle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058841

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

1.  CD8+ T cells in human uterine endometrial lymphoid aggregates: evidence for accumulation of cells by trafficking.

Authors:  G R Yeaman; J E Collins; M W Fanger; C R Wira; P M Lydyard
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

Review 2.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Generation of female genital tract antibody responses by local or central (common) mucosal immunization.

Authors:  H Y Wu; S Abdu; D Stinson; M W Russell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Sex dependent differences in physiological ageing in the immune system of lower airways in healthy non-smoking volunteers: study of lymphocyte subsets in bronchoalveolar lavage fluid and blood.

Authors:  E Mund; B Christensson; K Larsson; R Grönneberg
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

Review 5.  Immunoregulation of fetal and anti-paternal immune responses.

Authors:  Matthew M Seavey; Tim R Mosmann
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 6.  The endometrial immune environment of women with endometriosis.

Authors:  Júlia Vallvé-Juanico; Sahar Houshdaran; Linda C Giudice
Journal:  Hum Reprod Update       Date:  2019-09-11       Impact factor: 15.610

Review 7.  Immunobiology of genital tract trauma: endocrine regulation of HIV acquisition in women following sexual assault or genital tract mutilation.

Authors:  Mimi Ghosh; Marta Rodriguez-Garcia; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2012-10-04       Impact factor: 3.886

Review 8.  The immune system in menopause: pros and cons of hormone therapy.

Authors:  Mimi Ghosh; Marta Rodriguez-Garcia; Charles R Wira
Journal:  J Steroid Biochem Mol Biol       Date:  2013-09-13       Impact factor: 4.292

Review 9.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

Review 10.  Autoimmune diseases and reproductive aging.

Authors:  Riley Bove
Journal:  Clin Immunol       Date:  2013-02-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.